Drug intelligence / Profile preview

AMT-126

Development stage: Phase 1
Lead developer: Cyclo Therapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Gene Therapies
Administration: Oral

Overview

AMT-126 refers to two distinct therapeutic candidates developed by different companies. The first is an oral Interleukin-22 (IL-22) fusion protein developed by Applied Molecular Transport (AMT), now a subsidiary of Cyclo Therapeutics. This biologic utilizes a proprietary technology platform to enable active transport across the intestinal epithelium, aiming to treat ulcerative colitis and other diseases characterized by intestinal barrier defects by promoting mucosal healing. The second candidate was an adeno-associated virus (AAV) gene therapy program developed by uniQure in collaboration with Bristol Myers Squibb. This version of AMT-126 was designed to deliver the S100A1 gene to treat congestive heart failure by restoring calcium homeostasis in cardiomyocytes. However, the S100A1 gene therapy program was discontinued in 2018 after failing to demonstrate benefit in preclinical studies.

Other names: AMT-126 (IL-22)AMT-126 (S100A1)

Targets

IL-22R (Interleukin 22 Receptor)

Beyond the preview

Go deeper on AMT-126.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMT-126.

Explore the full profile